Companion diagnostics (CDx) development market growth is expected at a CAGR of 11% during the period 2024-2035

According to a recently published report by Roots Analysis, the increasing adoption of CDx-guided drug development along with the growing preference for personalized healthcare is driving the demand for companion diagnostic development services

Companion Diagnostics (CDx) Development Industry Overview

The global companion diagnostics (CDx) development market is anticipated to grow at a CAGR of 11% from 2024-2035, reaching USD 1.8 billion by 2035.

Companion diagnostics (CDx) are essential tools in personalized medicine, that enables the identification of patients who are most likely to benefit from a specific therapy. As the development of novel therapies advances, the demand for close to 170 companion diagnostics approved by the USFDA, and more than 140 under investigation for various disease indications is expected to grow significantly. However, CDx development faces various challenges, such as varying diagnostic thresholds and simultaneous submission of these diagnostics with drug applications. Despite these challenges, the potential to enhance patient care and have better therapeutic outcomes, especially for oncological disorders makes CDx development a critical focus area for regulatory authorities and the pharmaceutical industry. The aforementioned factors are likely to present lucrative market growth opportunities for contract service providers and the CDx development market is anticipated to grow faster in the coming years.

Browse 265+ figures and 330+ market data tables spread across 730+ pages and detailed Table of Content on “Companion Diagnostic (CDx) Development Market by Type of Service Offered, Type of Analytical Technique Used, Target Therapeutic Area, End User and Key Geographical Regions: Industry Trends and Global Forecasts, Till 2035” here: https://www.rootsanalysis.com/reports/companion-diagnostics-services/297.html

Market Drivers 

Several factors contribute to the growth of the companion diagnostics (CDx) development market. The updated regulatory requirements for therapeutic approval, technological innovation and the growing demand for personalized medicine are among the most important growth drivers of the CDx development market. Further, the substantial development seen in this industry is mainly the result of stringent drug approval guidelines and growing focus on developing patient centric tailored treatments. Furthermore, the increasing adoption of companion diagnostics (CDx)-guided drug development, coupled with the lack of well-equipped infrastructure and expertise among drug developers for CDx development, is likely to lead to a rise in the outsourcing of CDx development to service providers. In addition, service providers are dedicated to upgrading their services by integrating advanced technologies like artificial intelligence and machine learning. This integration aims to elevate the quality of companion diagnostic development and optimize services, ensuring that they align with regulatory requirements to accelerate the drug approval process for serious and life-threatening diseases. Therefore, many drug developers are compelled to outsource the CDx development operations to contract service providers, thereby contributing to the growth of this market.

Market Restraints 

The process of CDx development is complex and challenging due to several factors. One of the primary restraints of this industry is the identification of predictive biomarkers that classify patients into responders and non-responders for a specified therapeutic agent. This step is hampered by the limited availability of genomic and clinical data. In addition, the discovery and development of CDx is a cost-intensive process, requiring specialized workforce, facilities and cutting-edge technologies, which can limit drug developer’s ability to manage the complexities associated with CDx development. The lack of expertise and a skilled workforce can further hinder the optimization of the CDx development process. These challenges highlight the need for a more streamlined and efficient approach to CDx development, which can facilitate the implementation of personalized medicine.

Growth Factors

Despite several challenges, various growth factors continue to drive the companion diagnostic (CDx) development market. It is worth noting that several service providers have expanded their service portfolio to include end-to-end CDx development services by using different analytical techniques, thereby offering a wide range of services to developers. In addition, various service providers claim to offer services by integrating advanced technologies such as artificial intelligence and machine learning algorithms, ensuring high-quality companion diagnostic development and providing efficient services. In fact, several service providers have a well-established global network of research labs and facilities to streamline the co-development of companion diagnostic and therapeutic products. Additionally, stringent regulatory guidelines by regulatory authorities, such as the USFDA and EMA has accelerated growth of this market. Moreover, collaborations with pharmaceutical companies, academic institutions and research organizations to address the growing demand for companion diagnostic across the world, is likely to drive considerable growth in the market.

Companion Diagnostic (CDx) Development Market Segments 

Based on the type of service offered, the market is segmented into Feasibility Studies, Assay Development, Analytical Validation, Clinical Validation and Manufacturing.

• The clinical validation segment led the companion diagnostic (CDx) development market, capturing the largest revenue share of 45% in 2024.
• The feasibility studies segment is anticipated to show an annual growth rate of 12.06%, during the forecast period.

Based on the type of analytical technique used, the market is segmented into NGS, PCR, IHC, Flow Cytometry and Other Analytical Techniques.

• The NGS segment led the companion diagnostic (CDx) development market, capturing the largest revenue share of close to 65% in 2024.
• The PCR segment is anticipated to show an annual growth rate of around 12%, during the forecast period.

Based on the target therapeutic area, the market is segmented into Oncological Disorders and Non-oncological Disorders.

• CDx development for oncological disorders led the companion diagnostic (CDx) development market, capturing the largest revenue share of 93% in 2024.
• The companion diagnostic development for non-oncological disorders segment is anticipated to show an annual growth rate of over 16.7%, during the forecast period.

Based on the end user, the market is segmented into Industry Players and Non-Industry Players.

• The industry players segment has led the companion diagnostic (CDx) development market, capturing the largest revenue share of 90% in 2024.
• In fact, the industry players segment is anticipated to witness the highest market growth rate of 11.2%, annually during the forecast period.

Based on the Key Geographical Regions, the market is segmented into North America, Europe and Asia-Pacific.

• North America dominated the companion diagnostic (CDx) development market and accounted for the largest revenue share of 66% in 2024.
• In Asia-Pacific, the companion diagnostic (CDx) development market is anticipated to demonstrate lucrative growth of 11.3% during the forecast period.

Key Companies Profiled

The companion diagnostic (CDx) development market report also includes detailed profiles of key players (listed below) that offer services for companion diagnostic (CDx) development:

• Almac Diagnostic Services
• BGI Genomics
• Eurofins
• Geneuity Clinical Research Services
• Labcorp
• MEDICAL & BIOLOGICAL LABORATORIES
• Q² Solutions
• QIAGEN
• Quest Diagnostics
• ResearchDx

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/companion-diagnostics-services/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com